Insilico Medicine nominates AI-driven drug candidate for cancer, Cushing’s syndrome and obesity
The NR3C1 (nuclear receptor subfamily 3 group C member 1) gene encodes the glucocorticoid receptor (GR), a nuclear receptor very ...
The NR3C1 (nuclear receptor subfamily 3 group C member 1) gene encodes the glucocorticoid receptor (GR), a nuclear receptor very ...
OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the ...
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 ...
Cancer immunotherapy, which primes the body's immune system to fight off tumors, has historically focused on harnessing T cells' natural ...
iLexx / iStock CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) announced today that it is awarding $1.1 million to biotechnology company ...
Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help restore vision ...
Insilico Medication("Insilico"), a clinical-stage generative synthetic intelligence (AI)-driven drug discovery firm, has efficiently delivered the second preclinical candidate compound (PCC) ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.